While Luxturna has paved the way for gene therapy in retinal diseases, it is important to highlight other promising therapies in clinical trials, such as those targeting X-linked retinitis pigmentosa (RPGR) and Leber congenital amaurosis (CEP290), to provide a broader view of future treatments. The gene discussed is CEP290; the disease is Abnormal retinal morphology.